<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04105010</url>
  </required_header>
  <id_info>
    <org_study_id>DZ2019J0005</org_study_id>
    <nct_id>NCT04105010</nct_id>
  </id_info>
  <brief_title>Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)</brief_title>
  <official_title>A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4205 in Patients With Peripheral T Cell Lymphoma (PTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dizal Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dizal Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multinational, non-randomized, open-label, Phase 1/2 clinical study to evaluate the&#xD;
      safety, tolerability and anti-tumor efficacy of AZD4205 as monotherapy in patients with&#xD;
      peripheral T cell lymphoma (PTCL), who have relapsed from or are refractory/intolerant to&#xD;
      standard systemic treatment.&#xD;
&#xD;
      Phase 1 part:&#xD;
&#xD;
      Around 20~40 patients will be subsequently enrolled into 2 different dose ascending cohorts.&#xD;
      Additional 10~20 patients may be enrolled to further explore a selected dose defined by dose&#xD;
      escalation cohorts.&#xD;
&#xD;
      Phase 2 part:&#xD;
&#xD;
      After the recommended phase 2 dose (RP2D) is defined, a phase 2 single-arm open-label pivotal&#xD;
      study will be conducted to assess anti-tumor efficacy and safety of AZD4205 at RP2D in&#xD;
      patients with refractory or relapsed PTCL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>ORR is the percentage of patients with at least one visit response of Complete Response (CR) or Partial Response (PR) based on CT scans per Lugano criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>The first dose until 28 days after last dose</time_frame>
    <description>To evaluate the safety and tolerability of AZD4205 in patients with PTCL in terms of adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of AZD4205</measure>
    <time_frame>1,8,15, 21 days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of AZD4205</measure>
    <time_frame>1,8,15, 21 days after first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Relapsed or Refractory Peripheral T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>AZD4205 Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: Open label AZD4205 at dose A, once daily (Phase 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD4205 Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B: Open label AZD4205 at dose B, once daily (Phase 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD4205 Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group C: Open label AZD4205 at a selected dose, once daily (Phase 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD4205 Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group D: Open label AZD4205 at the RP2D, once daily (Phase 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD4205</intervention_name>
    <description>AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions</description>
    <arm_group_label>AZD4205 Group A</arm_group_label>
    <arm_group_label>AZD4205 Group B</arm_group_label>
    <arm_group_label>AZD4205 Group C</arm_group_label>
    <arm_group_label>AZD4205 Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Obtained written informed consent&#xD;
&#xD;
          2. Patients must have histologically confirmed peripheral T-cell lymphoma according to&#xD;
             the 2016 revision of the World Health Organization classiﬁcation of lymphoid&#xD;
             neoplasms. Tumor samples are required for central pathology review to confirm the&#xD;
             diagnosis.&#xD;
&#xD;
          3. Patients must have measurable disease according to the Lugano criteria.&#xD;
&#xD;
          4. Patients should be transplant-ineligible upon their entry into this study, and must&#xD;
             have relapsed after or been refractory/intolerant to ≥ 1 (but not &gt; 3) prior systemic&#xD;
             therapy(ies) for PTCL.&#xD;
&#xD;
          5. Adequate bone marrow reserve and organ system functions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any unsolved toxicity &gt; Common Terminology Criteria for Adverse Events (CTCAE) grade 1&#xD;
             from previous anti-cancer therapy (except alopecia).&#xD;
&#xD;
          2. Active infections, active or latent tuberculosis.&#xD;
&#xD;
          3. Patients with severely decreased lung function.&#xD;
&#xD;
          4. History of heart failure or QT interval prolongation.&#xD;
&#xD;
          5. Central nervous system (CNS) or leptomeningeal lymphoma.&#xD;
&#xD;
          6. History of treatment with Janus kinase (JAK) or signal transducer and activator of&#xD;
             transcription 3 (STAT3) inhibitor.&#xD;
&#xD;
          7. Patient has undergone an allogeneic stem cell transplant. Patient had autologous stem&#xD;
             cell transplant within 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Seog Kim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Li, MD</last_name>
    <phone>862161097868</phone>
    <email>jason.li@dizalpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Yang, MD, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Foss</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan University - West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Song</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Do</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eom</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwak</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06133</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koh</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

